News

BlogsPosts
Press Release
RepliCel Life Sciences Inc. Announces Closing of Brokered and Non-brokered Private Placement
NOT FOR DISTRIBUTION TO UNITED STATES NEWS WIRE SERVICES OR FOR DISSEMINATION IN THE UNITED
BlogsPosts
Press Release
RepliCel Life Sciences Announces Brokered Private Placement
NOT FOR DISTRIBUTION TO UNITED STATES NEWS WIRE SERVICES OR FOR
BlogsPosts
Press Release Event
RepliCel Life Sciences Selected to Present at Cavendish Global Health Impact Forum
Unique forum brings together leading family offices and foundations seeking impactful investment and philanthropic opportunities
BlogsPosts
Press Release
RepliCel Announces 2014 Fourth Quarter and Year-End Financial Results
VANCOUVER, BC – April 29, 2015 – RepliCel Life Sciences Inc. (OTCQB: REPCF) (TSXV: RP),
BlogsPosts
Press Release
RepliCel Life Sciences Receives Approval to Conduct Clinical Trial for Patients with Chronic Achilles Tendinosis
The University of British Columbia Clinical Research Ethics Board Clears Clinical Trial to Proceed with
BlogsPosts
Press Release
RepliCel Life Sciences Receives TSX Venture Exchange Approval to Extend Warrant Expiry Dates
VANCOUVER, BC – April 7, 2015 – RepliCel Life Sciences Inc. (the “Company” or “RepliCel”)
BlogsPosts
Press Release
RepliCel Life Sciences Applies to Extend Warrant Expiry Dates
VANCOUVER, BC – April 2, 2015 – RepliCel Life Sciences Inc. (the “Company” or “RepliCel”)
BlogsPosts
Press Release
RepliCel Meets with Japanese Pharmaceutical and Medical Devices Agency (PMDA)
As part of its Japanese partnering strategy, RepliCel seeks advice of Japanese regulators around its
BlogsPosts
Press Release
RepliCel Life Sciences in Japan for Key Industry Meetings
Autologous cell therapy, RCS-01, to be investigated as a potential treatment for aged, UV-damaged skin
BlogsPosts
Press Release
RepliCel Submits Clinical Trial Application for its Dermatological Clinical Trial
Autologous cell therapy, RCS-01, to be investigated as a potential treatment for aged, UV-damaged skin
BlogsPosts
Press Release
Newly Released Peer-Reviewed Publication Further Validates RepliCels Use of Dermal Sheath Cup Cells to Treat Pattern Baldness
VANCOUVER, BC – December 22, 2014 – RepliCel Life Sciences Inc. (OTCQB: REPCF) (TSX.V: RP),
BlogsPosts
Press Release
RepliCel Life Sciences Receives Health Canada Clearance for Clinical Trial in Patients with Chronic Achilles Tendinosis
Health Canada Issues “No Objection Letter” for RepliCel’s Phase 1/2 Clinical Trial of RCT-01
BlogsPosts
Press Release
RepliCel Announces 2014 Third Quarter Financial Results
VANCOUVER, BC – November 26, 2014 – RepliCel Life Sciences Inc. (the “Company” or “RepliCel”)
BlogsPosts
Press Release
RepliCel Submits Clinical Trial Application to Health Canada for its Chronic Achilles Tendinosis Trial
Autologous cell therapy, RCT-01, to be investigated for treatment of tendinopathies refractory to other treatments
BlogsPosts
Press Release
RepliCel Life Sciences Adds Industry Specialist to Management Team
Newly Appointed Vice-President of Business & Corporate Development to Drive External Initiatives
BlogsPosts
Press Release
RepliCel Retains Market-Making Services
VANCOUVER, BC – September 12, 2014 – RepliCel Life Sciences Inc. (TSXV: RP) (OTCQB: REPCF)
BlogsPosts
Press Release
RepliCel Garners Feature on Fox Business News and the Financial Post
RepliCel’s Innovative Technology Converts Your Own Cells into Products to Repair and Rejuvenate the Body
BlogsPosts
Press Release
RepliCel Life Sciences Joins Centre for Commercialization of Regenerative Medicine, Industry Consortium
CCRM and RepliCel to Partner on Development of Cell Therapies for Tendon Repair
BlogsPosts
Press Release
RepliCel Announces 2014 Second Quarter Financial Results
VANCOUVER, BC – August 26, 2014 – RepliCel Life Sciences Inc. (the “Company” or
BlogsPosts
Press Release
RepliCel Appoints Brooke Hurford as Corporate Secretary and Director, Finance
VANCOUVER, BC – July 16, 2014 – RepliCel Life Sciences Inc. (the “Company”) (TSXV: RP)

DISCLAIMER:
The information in these press releases is historical in nature, has not been updated, and is current only to the date indicated in the particular press release. This information may no longer be accurate and therefore you should not rely on the information contained in these press releases. To the extent permitted by law, RepliCel Life Sciences Inc. and its employees, agents and consultants exclude all liability for any loss or damage arising from the use of, or reliance on, any such information, whether or not caused by any negligent act or omission.

THIRD PARTY CONTENT
Please note that any opinion, estimates or forecasts made by the authors of these statements are theirs alone and do not represent opinions, forecasts or predictions of RepliCel Life Sciences Inc. or its management. RepliCel Life Sciences Inc. does not, by its reference or distribution of these links imply its endorsement of, or concurrence with, such information, conclusions or recommendations.